Johnson & Johnson Secures FDA Approval for Oral Psoriasis Drug

FDA Approves J&J's First-in-Class Oral Psoriasis Pill on March 18

Johnson & Johnson (NYSE: JNJ) secured U.S. Food and Drug Administration (FDA) approval on March 18, 2026, for ICOTYDE™ (icotrokinra), its new treatment for moderate-to-severe plaque psoriasis. The approval covers adults and pediatric patients aged 12 and older who are candidates for systemic therapy. ICOTYDE is the first and only targeted oral peptide that precisely blocks the interleukin-23 (IL-23) receptor, a key driver of the disease, providing a novel mechanism of action in a simple, once-daily pill.

ICOTYDE Enters Crowded Market with Convenience Advantage

This approval allows Johnson & Johnson to enter the competitive dermatology market with a highly differentiated product. While numerous biologic treatments for psoriasis exist, many require injections. ICOTYDE's oral administration offers a significant convenience advantage for patients seeking to manage their chronic condition without the burden of regular shots. The drug aims to address the needs of patients cycling through topical therapies who require a more effective systemic solution.

ICOTYDE delivers something unique in psoriasis treatment – combining skin clearance with a favorable safety profile in a once–daily pill, making it an easy addition to a patient's routine.

— Linda Stein Gold, M.D.

March Approval Streak Underscores J&J's Pipeline Strength

The successful approval of ICOTYDE is part of a broader trend of regulatory success for Johnson & Johnson in early 2026. Earlier in March, the company also gained FDA approval for its Tecnis PureSee IOL, an advanced lens for cataract surgery. Additionally, the FDA granted Fast Track designation to nipocalimab, another J&J drug for treating systemic lupus erythematosus. This pattern of positive regulatory outcomes highlights the strength and execution of the company's pharmaceutical and medical device pipeline, reinforcing investor confidence in its long-term growth strategy.